WP Anticoagulant Peptide DLRVM (Whitmania pigra)
5-residue thrombin-binding anticoagulant peptide from Whitmania pigra hydrolysate — Liu 2024 docking + activity validation.
Praeklinisch / mechanistischLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 5-residue thrombin-binding anticoagulant peptide from Whitmania pigra hydrolysate — Liu 2024 docking + activity validation.
- Evidence level
- In vitro
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
DLRVM peptide's in vitro anticoagulant activity does NOT establish clinical efficacy. No FDA-approved derivative; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 645 Da
- Source species
- Whitmania pigra
- Discovered
- 2024 · Liu YX et al.
Biological Targets
- → thrombin (Factor IIa)
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.